Oral use of human alpha interferon in cats.
1988; National Institutes of Health; Volume: 7; Issue: 5 Linguagem: Inglês
Autores
Joseph Μ. Cummins, Mary B. Tompkins, R. G. Olsen, W. A. F. Tompkins, Mark G. Lewis,
Tópico(s)Hepatitis B Virus Studies
ResumoLow doses (0.5 or 5.0 U) of human alpha interferon (HuIFN alpha) given orally prevented the experimental development of fatal feline leukemia virus (FeLV)-related disease. Twenty-one FeLV-susceptible cats were inoculated with the Rickard strain of FeLV. Cats given oral HuIFN alpha survived significantly (p less than 0.001) longer than untreated FeLV-infected cats. Moreover, only 4 of 13 (30.8%) HuIFN alpha-treated cats developed clinical disease during the course of the study, whereas 100% of the untreated control cats developed fatal FeLV-related disease. Thus, in experimental retroviral disease, heterologous species HuIFN alpha provided significant clinical benefits.
Referência(s)